Cancer vaccine therapy using epitope peptide from CDH3 restricted to HLA-A*2402 with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer (Phase I study)
Phase 1
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000005549
- Lead Sponsor
- Sapporo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pregnancy or lactation 2)Patients with the intention of pregnancy. 3)Patients have uncontrollable severe infectional diseases. 4)Patients who are treated with steroid or immunotherapy during clinical trial. 5)Patients have uncontrollable multiple cancer. 6)Patients who have non-recovered injury. 7)Patients who have ileus and interstitial lung disiease. 8)Patients whom doctors define as inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Immunological response, Antitumor efficacy, Time to progression, Overall survival